Currently Viewing:
COA Community Oncology Conference 2019
COA Close to Filing OCM 2.0 for Federal Review
April 05, 2019
Strategies for Fighting Consolidation in Community Oncology
April 05, 2019
Katie Goodman: Bring Clinical Trials to the Community Setting to Meet Patients Where They Are
April 05, 2019
Dr Howard Burris on Efforts Needed to Ensure Access to NGS Testing
April 05, 2019
Dr Lee Schwartzberg Explains the Promise of Liquid Biopsies in Cancer
April 06, 2019
Dr C.K. Wang Discusses How Real-World Data Can Benefit Payers
April 06, 2019
Pharma Discusses How to Reframe Value in Era of Precision Medicine, Combinations
April 06, 2019
Step Therapy in Medicare Advantage Hurts Patients, Providers, Says Schwartzberg
April 06, 2019
Dr Basit Chaudhry Outlines Findings From OCM PP3
April 07, 2019
Dr Jeffrey Scott on Pharma's Role in Understanding the Value of Novel, Expensive Therapies
April 07, 2019
Dr Jeff Patton on OCM PP3 Results, Challenges With the Model
April 09, 2019
Dr Sonia T. Oskouei Discusses Uptake, Cost Savings With Filgrastim Biosimilar Xarzio
April 11, 2019
Katie Goodman on FDA's Efforts to Expand Patient Inclusion Criteria for Clinical Trials
April 11, 2019
Dr Lee Schwartzberg Reflects on the Approval of the First Immunotherapy Regimen in Breast Cancer
April 12, 2019
Dr C.K. Wang on How Real-World Data Provide a More Comprehensive Picture of Drug Efficacy
April 14, 2019
Dr Basit Chaudhry on Challenges With Improving Performance Under OCM
April 17, 2019
Dr Jeff Patton Explains How Physician Shortage, Burnout Are Impacting Community Oncologists
April 22, 2019
Dr Lee Schwartzberg on Genetic Testing for All Patients Diagnosed With Breast Cancer
April 23, 2019
Dr Sonia Oskouei Explains the Importance of Education Around Biosimilars
April 24, 2019
Katie Goodman Discusses Clinical Trial Participation Criteria's Impact on Trial Participation
April 25, 2019
Currently Reading
Dr C.K. Wang: How COTA's Real-World Data Platform Helps Oncologists Make Informed Decisions
April 27, 2019
Dr Basit Chaudhry: Evaluating the Adequacy of Novel Therapy Adjustment Under OCM
April 29, 2019
Dr Lee Schwartzberg Outlines Challenges With Accessing Multigene Testing in the Community Setting
May 07, 2019
Dr Jeff Patton Discusses CMS' Proposal to Ease Protections on 6 Drug Classes in Part D
May 08, 2019

Dr C.K. Wang: How COTA's Real-World Data Platform Helps Oncologists Make Informed Decisions

In addition to helping make treatment decisions, COTA's real-world data platform can help oncologists understand and identify areas where there is treatment variability and help them work to contain cost in the long run, explained C.K. Wang, MD, senior medical director, COTA.


In addition to helping make treatment decisions, COTA's real-world data platform can help oncologists understand and identify areas where there is treatment variability and help them work to contain cost in the long run, explained C.K. Wang, MD, senior medical director, COTA.

Transcript

How does COTA’s real-world data platform help oncologists make decisions about their patients?

Oncologists today in coming up with a treatment plan, first of all, it’s a very complex process, but they resort to multiple sources. First and foremost is drug approvals. Secondly, the well-established treatment guidelines, and third, clinicians often draw from their own personal experience. That said, the patients that are sitting in from of them may not fit into any of those previous constructs. For example, today, only 3% to 5% of cancer patients participate in clinical trials, which ultimately lead to drug approvals. It is likely that patient sitting in front of the provider in that patient population was never represented or was not well-represented in that clinical trial.

So, what real-world data does and what COTA’s platform can do is to surface real-world treatment approaches for those patients, as well as real-world toxicities and outcomes. All of these different factors can help a clinician then ultimately make the best treatment decision for the patient. Now that said, real-world data and COTA’s platform is currently not being used at the point of care, but there are many exploratory discussions looking into this. I think that ultimately, how this can benefit providers, in addition to making treatment decisions, is to allow them insight into how they’ve treated these patients in the past, and therefore understand and identify areas where there is tremendous treatment variability and help them work to contain cost in the long run.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up